臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 201-225 / 881 (共36頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-09-01T01:53:41Z	Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers	Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏	2021-09-01T01:53:40Z	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study	Hsu C.; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:27Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:27Z	Reply	Hsu C.; Chen P.-J.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:25Z	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma	Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:24Z	Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin	Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:22Z	Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity	Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:18Z	Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma	Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:50Z	Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)	Hsu C.; Chen B.-B.; Chen C.-H.; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:49Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; ANN-LII CHENG; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2021-08-31T06:29:46Z	Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy	Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F.
臺大學術典藏	2021-08-31T06:29:44Z	Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges	Lu L.-C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:43Z	Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression	Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG; Ou D.-L.
臺大學術典藏	2021-08-31T06:29:42Z	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer	Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; ANN-LII CHENG; Kuo S.-H.
臺大學術典藏	2021-08-31T06:29:36Z	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma	Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F.
臺大學術典藏	2021-08-31T06:29:34Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C.
臺大學術典藏	2021-08-31T06:29:32Z	Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy	Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C.
臺大學術典藏	2021-08-31T06:29:29Z	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan	Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group
臺大學術典藏	2021-08-31T06:29:27Z	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection	Yang H.-C.; Tsou H.-H.; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group
臺大學術典藏	2021-08-31T06:29:25Z	Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma	Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; ANN-LII CHENG; Hsu C.
臺大學術典藏	2021-08-31T06:29:23Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:22Z	Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma	Lin Z.-Z.; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:21Z	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients	Yang S.-H.; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏	2021-08-31T06:29:21Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:29:21Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; ANN-LII CHENG

顯示項目 201-225 / 881 (共36頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52880926 線上人數 : 666 教育部委託研究計畫計畫執行:國立臺灣大學圖書館